Effects of calcium antagonist diltiazem on leukocyte elastase and on reactive oxygen species production in human neutrophils.
During inflammatory disorders, some proteases and very reactive oxygen metabolites are produced by activated phagocytic cells. These proteases and oxidants are involved in many diseases like tissue injury or atherosclerosis. It was shown in vitro that diltiazem, a calcium channel blocker, had antielastase and antioxidant properties. This drug inhibited the release of elastase by neutrophils in a dose dependent manner when these cells were stimulated by phorbol-myristate-acetate (PMA) or by formyl-methionyl-leucylphenylalanine (fMLP) with an IC50 of 144.5 microM, and 132.8 microM, respectively. Towards the oxidants, the 50% inhibitory concentrations (IC50) of diltiazem are 422 microM, 138 microM and 165 microM for superoxide anion, hypochlorous acid and hydroxyl radical production by PMA stimulated human neutrophils, respectively. In the case of fMLP stimulated human neutrophils, the IC50 for superoxide anion is 78 microM. When human neutrophils were stimulated by dioctanoylglycerol (DiC8) or by calcium ionophore (Ca.I), the IC50 for superoxide anion were 175.5 microM and 186 microM, respectively. When human neutrophils were stimulated by opsonized zymosan (OZ), diltiazem did not show an inhibition of superoxide production in a dose dependent manner. This drug did not act by scavenging elastase or oxidants as demonstrated by cell free models. A mechanism of elastase and oxygen metabolites inhibition by diltiazem has been considered specially toward the mobilization of cytosolic calcium and an inhibition of protein kinase C cannot be excluded. The results suggest that diltiazem might contribute to attenuate the development and the progression of atheroma where oxidants and elastase have been implicated.
Khalfi
F
F
Laboratoire de Pharmacologie, Faculté des Sciences Pharmaceutiques et Biologiques, Lille, France.
Gressier
B
B
Brunet
C
C
Dine
T
T
Luyckx
M
M
Cazin
M
M
Cazin
J C
JC
D004110:Diltiazem / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019272:Leukocyte Elastase / Q000187:drug effects*; D009504:Neutrophils / Q000187:drug effects*; D010100:Oxygen / Q000378:metabolism*
D019272:Leukocyte Elastase; D004110:Diltiazem; D010100:Oxygen